



Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : I /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 10:03 a.m.

Reporting Time: Mar 08, 2025, 01:19 p.m.

250308057

Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

Test Description Value(s) Unit(s) Reference Range

HAEMATOLOGY

Complete Haemogram - Hb RBC count and indic	ces, TLC, DLC, PLAT	 ELET, ESR.(EDTA \	Whole Blood)
Hemoglobin (Hb)	12.6	g/dL	12.0 - 15.0
Method : Whole Blood, SLS-haemoglobin			
Erythrocyte (RBC) Count	5.37	x 10^6/uL	3.8 - 4.8
Method : Whole Blood, DC detection			
HCT	41.0	%	36 - 46
Method: Whole Blood, RBC pulse height detection			
Mean Cell Volume (MCV)	76.4	fL	83 - 101
Method : Whole Blood, Electrical Impedence			
Mean Cell Haemoglobin (MCH)	23.5	pg	27 - 32
Method : Whole Blood, Calculated			
Mean Corpuscular Hb Concn. (MCHC)	30.7	g/dL	32.0 - 35.0
Method : Whole Blood, Calculated			
Red Cell Distribution Width (RDW) CV	14.1	%	11.6 - 14.0
Method : Whole Blood, Calculated			
Total Leucocytes (WBC) Count	8.3	x 10^3 /uL	4 - 10
Method : Whole Blood, Flow cytometry			
DLC (Differential Leucocytes Count)			
Neutrophils	67.3	%	40 - 80
Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy			
Lymphocytes	23.7	%	20 - 40
Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy			
Monocytes	4.8	%	2 - 10
Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy			
Eosinophils	3.6	%	1 - 6
Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy			
Basophils	0.6	%	0 - 2
Method : Whole Blood, Fluorescence /Flowcytometry/ Microscopy			
Absolute Neutrophil Count	5.59	x 10^3/uL	2.0 - 7.0
Method : Whole Blood, Calculated			
Absolute Lymphocyte Count	1.97	x 10^3/uL	1 - 3
Method : Whole Blood, Calculated		_	
Absolute Monocyte Count	0.40	x 10^3u/L	0.2-1.0
Method : Whole Blood, Calculated			
Absolute Eosinophil Count	0.30	x 10^3/uL	0.02 - 0.5
Method : Whole Blood, Calculated			
Absolute Basophils Count	0.05	x 10^3/uL	0.02 - 0.1
Method : Whole Blood, Calculated	004	4040/-1	450 440
Platelet Count	231	x 10^3/uL	150 - 410
Method : Whole Blood, DC Detection			





Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : I /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 10:03 a.m.

Reporting Time: Mar 08, 2025, 01:19 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range
ESR - Erythrocyte Sedimentation Rate	35	mm/hr	<20
Method: Whole blood, Modified Westergren Method			

Interpretation:

DMC No: 43012

It indicates presence and intensity of an inflammatory process. It is a prognostic test and used to monitor the course or response to treatment of diseases like tuberculosis, acute rheumatic fever,. It is also increased in multiple myeloma, hypothyroidism.

Tests done on Automated Six Part Cell Counter.

END OF REPORT



Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : I /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 10:03 a.m.

Reporting Time: Mar 08, 2025, 01:19 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range		
<u>IMMUNOLOGY</u>					
T3, T4, TSH (Thyroid Profile Total),Serum					
(Triiodothyronine) T3-Total	0.93	ng/mL	0.80 - 2.00		
Method : ECLIA					
(Thyroxine) T4-Total	7.16	ug/dL	5.10 - 14.10		
Method : ECLIA					
TSH-Ultrasensitive	1.07	uIU/mL	0.27-4.20		
Method : ECLIA					
Interpretation					

The Biological reference interval provided is for Adults.

For age specific reference interval, please refer to the table given below.

тѕн	T3/FT3	T4/FT4	Interpretation
High	Normal	Normal	Subclinical Hypothyroidism
Low	Normal	Normal	Subclinical Hyperthyroidism
High	High	High	Secondary Hypothyroidism
Low	High/Normal	•	Hyperthyroidism
Low	Low	Low	Non Thyroidal illness/Secondary Hyperthyroidism

TSH (mU/mL)				
	New Born	0.7	15.2	
Childern 4 -12 Mon	6 days - 3 Months	0.72	11	
	4 -12 Months	0.73	8.35	
	1-6 Years	0.7	5.97	
	7-11 Years	0.6	4.84	
	12-20 years	051	4.3	
Adults		0.27	4.20	

TSH levels are subjected to circadian variation, rising several hours before the onset of sleep, reaching peak levels between 11 pm and 6 am. Nadir concentration are observed during the afternoon. diurnal variation in TSH levels is approx 50%+/-, hence time of the day can influence the measured serum concentration.

END OF REPORT

Dr. Arti Tripathi MD Pathology Lab Director DMC No: 43012



Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : I /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)

Method : Oxidase Reaction/ Manual



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 02:43 p.m.

Reporting Time: Mar 08, 2025, 05:38 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

Test Description

Value(s)
Unit(s)

Reference Range

CLINICAL PATHOLOGY

Urine Glucose (Fasting & PP)

Glucose Fasting (Urine)
Method: Oxidase Reaction/ Manual

Glucose Post Prandial (Urine)
Negative
Negative

END OF REPORT

Dr. Arti Tripathi MD Pathology Lab Director DMC No: 43012



Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : I /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 10:03 a.m.

Reporting Time: Mar 08, 2025, 01:19 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

Test Description Value(s) Unit(s) Reference Range

HAEMATOLOGY

Blood Group (ABO)

Blood Group

"A"

Method : Forward and Reverse by Slide method

RH Factor

Positive

Methodology

This is done by forward and reverse grouping by slide agglutination method.

Interpretation

MD Pathology Lab Director DMC No: 43012

Newborn baby does not produce ABO antibodies until 3 to 6 months of age. So the blood group of the Newborn baby is done by ABO antigen grouping (forward grouping) only, antibody grouping (reverse grouping) is not required. Confirmation of the New-born's blood group is indicated when the A and B antigen expression and the isoagglutinins are fully developed (2–4 years).

END OF REPORT

66A/3, Pal Mohan Bhawan, New Rohtak Road, New Delhi-110005

Phone: +919212200575, Email: info@malvindiagnostics.com, Website: www.malvindiagnostics.com
Please correlate the test results with clinical history of the patient. Not for medico-legal purpose.





Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No.: | /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 10:03 a.m.

Reporting Time: Mar 08, 2025, 01:19 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range		
BIOCHEMISTRY					
LFT (Liver Function Test, Serum)					
Total Protein	7.8	g/dL	6.6 - 8.7		
Method : Biuret Method					
Albumin	4.4	g/L	3.5 - 5.2		
Method : Bromocresol Green (BCG)					
Globulin	3.40	g/dL	1.8 - 3.6		
Method : Calculated					
A G Ratio	1.29	ratio	1.2 - 2.2		
Method : Calculated					
SGOT	18	U/L	5 to 32		
Method : IFCC with Pyridoxal Phosphate					
SGPT	16	U/L	10-35		
Method : IFCC with Pyridoxal Phosphate					
Alkaline Phosphatase ALP	97	U/L	35-104		
Method : PNP AMP Kinetic					
GGT-Gamma Glutamyl Transferase	10	U/L	5-36		
Method : IFCC					
Bilirubin Total	0.30	mg/dL	0.2-1.2		
Method : Diazo Method					
Bilirubin Direct	0.10	mg/dL	0.09 - 0.30		
Method : Diazo Method					
Bilirubin Indirect	0.20	mg/dL	0.1 - 1.0		
Method : Calculated					
Interpretation.					

Interpretation:

SGOT/ SGPT: Increased in Acute viral hepatitis, Biliary tract obstruction (cholangitis, choledocholithiasis), Alcoholic hepatitis and Cirrhosis, liver abscess, metastatic or primary liver cancer; non-alcoholic steatohepatitis; right heart failure. Decreased in Pyridoxine (vit B6) deficiency.

Alkaline Phosphatase: Increased in Obstructive hepatobiliary disease, Bone disease (physiologic bone growth, Paget disease, Osteomalacia, Osteogenic sarcoma, Bone metastases), Hyperparathyroidism, Rickets, Pregnancy (third trimester). Decreased in Hypophosphatasia.

GGT: Increased in Liver disease Acute viral or toxic hepatitis, Chronic or subacute hepatitis, Alcoholic hepatitis, Cirrhosis, Biliary tract obstruction.

Protein: Moderate-to-marked hyperproteinemia maybe due to multiple myeloma and other malignant paraproteinemias, Hypoproteinemia may be due to decreased production or increased protein loss.

Albumin: Increased in Dehydration, Shock, Hemoconcentration. Decreased in hepatic synthesis(Chronic liver disease, malnutrition, malabsorption, malignancy), Increased losses (Nephrotic syndrome, Burns, Trauma, Hemorrhage with fluid replacement, acute or chronic glomerulonephritis), Hemodilution (pregnancy, CHF) and Drugs (estrogens).

Bilirubin: Elevated levels of bilirubin (jaundice) might indicate liver damage or disease or certain types of anemia.

END OF REPORT





Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : I /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 10:03 a.m.

Reporting Time: Mar 08, 2025, 01:19 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

Test Description Value(s) Unit(s) Reference Range

Dr. Arti Tripathi MD Pathology Lab Director DMC No: 43012





Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No.: 1 /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 10:03 a.m.

Reporting Time: Mar 08, 2025, 01:19 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range	
	BIOCHE	MISTRY		
KFT (Renal Function Test, Serum)				
Urea	20.4	mg/dL	16.6-48.5	
Method : Urease-GLDH				
Creatinine	0.50	mg/dL	0.6-1.1	
Method : Jaffe Method				
Uric Acid	3.8	mg/dL	2.4-5.7	
Method : Uricase-POD				
Potassium	-	mmol/L	3.5-5.3	
Method : ISE Direct				
Interpretation :				

Interpretation:

Urea:- Increased in renal diseases, urinary obstructions, shock, congestive heart failure . Decreased in liver failure and pregnancy.

Creatinine:- Elevated in renal dysfunction, reduced renal blood flow shock, dehydration, Congestive heart failure, Diabetes Acromegaly. Decreased levels are found in Muscular Dystrophy.

Uric acid:- Increased in Gout, Arthiritis, impaired renal functions and starvation. Decreased in Wilson's disease, Fanconis Syndrome and Yellow Atrophy of Liver.

Sodium:-Increased in Excessive dietary salt ,Diuretic therapy,Adrenal insufficiency,Salt-wasting nephropathy and Vomiting.Decreased levels are seen in Hyperaldsteronism ,Hyponatremia,Prerenal Azotemia,Renal Failure and Glomerulonephritis.

Potassium:- Low levels is common in vomiting, diarrhea, alcoholism, and folic acid deficiency. Increase level are seen in end-stage renal failure, hemolysis, trauma, Addison's disease, metabolic acidosis, acute starvation, dehydration, and with rapid potassium infusion.

Chloride:- Increased in dehydration, renal tubular acidosis, acute renal failure, metabolic acidosis, diabetes insipidus, adrenocortical hyperfuction. Decreased in overhydration, chronic respiratory acidosis, salt-losing nephritis, metabolic alkalosis.

END OF REPORT

OMC No: 43012





Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : I /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 10:03 a.m.

Reporting Time: Mar 08, 2025, 01:19 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

Test Description	Value(s)	Unit(s)	Reference Range
	BIOCHE	MISTRY	
<u>Lipid Profile,Serum</u>			
Cholesterol-Total Method : CHOD-POD	207	mg/dL	Desirable: <= 200 Borderline High: 201-239 High: > 239 Ref: The National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.
Triglycerides Method: GPO-POD	112	mg/dL	Normal: < 150 Borderline High: 150-199 High: 200-499 Very High: >= 500
Cholesterol-HDL Direct Method : Homogenous Enzymatic	57	mg/dL	No Risk - \geq 60 mg/dL Moderate risk - 45-65 mg/dL High risk - $<$ 40 mg/dL
LDL Cholesterol Method : Calculate	127.60	mg/dL	Optimal: < 100 Near optimal/above optimal: 100-129 Borderline high: 130-159 High: 160-189 Very High: >= 190
Non - HDL Cholesterol Method : Calculated	150	mg/dL	Desirable: < 130 mg/dL Borderline High: 130-159mg/dL High: 160-189 mg/dL Very High: > or = 190 mg/dL
VLDL Cholesterol Method : Calculated	22.40	mg/dL	0 - 30
CHOL/HDL RATIO Method : Calculated	3.63	Ratio	3.5 - 5.0
LDL/HDL RATIO Method : Calculated	2.24	Ratio	Desirable / low risk - 0.5 -3.0 Low/ Moderate risk - 3.0- 6.0

END OF REPORT







Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No.: | /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 10:03 a.m.

Reporting Time: Mar 08, 2025, 01:19 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

Test Description Value(s) Unit(s) Reference Range

BIOCHEMISTRY

Glucose (Fasting), Plasma

Glucose Fasting 104 mg/dL Normal: 74-100

 Method : Hexokinase
 Impaired Tolerance: 100-125

 Diabetes mellitus: ≥ 126
 (on more than one occassion)

(American diabetes association

guidelines 2025)

Interpretation

Glycemic goals for Diabetes

Fasting Plasma Glucose	80-130 mg/dL
Post Prandial Plasma Glucose	<180 mg/dL

Glucose is the major carbohydrate present in the peripheral blood. Oxidation of glucose is the major source of cellular energy in the body. The concentration of glucose in blood is controlled within the narrow limits by many hormones, the most important of which are produced by the pancreas. The most frequent cause of hyperglycaemia is diabetes mellitus resulting from deficiency in insulin secretion or action. These include pancreatitis, thyroid dysfunction, renal failure, and liver disease. Hypoglycaemia is less frequently observed. A variety of conditions may cause low blood glucose levels such as insulinoma, hypopituitarism, or insulin induced hypoglycaemia.

END OF REPORT

DMC No: 43012





Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No.: | /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 02:43 p.m.

Reporting Time: Mar 08, 2025, 03:50 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

Test Description Value(s) Unit(s) Reference Range

BIOCHEMISTRY

Glucose (PP),Plasma

Blood Glucose-Post Prandial 88 mg/dL Normal :74 - 140

Method: Hexokinase Prediabetes: 140-199 2 hrs of OGTT

Diabetes : > 200 2 hrs

Interpretation

Glycemic goals for Diabetes

Fasting Plasma Glucose	80-130 mg/dL
Post Prandial Plasma Glucose	<180 mg/dL

Glucose is the major carbohydrate present in the peripheral blood. Oxidation of glucose is the major source of cellular energy in the body. The concentration of glucose in blood is controlled within the narrow limits by many hormones, the most important of which are produced by the pancreas. The most frequent cause of hyperglycaemia is diabetes mellitus resulting from deficiency in insulin secretion or action. These include pancreatitis, thyroid dysfunction, renal failure, and liver disease. Hypoglycaemia is less frequently observed. A variety of conditions may cause low blood glucose levels such as insulinoma, hypopituitarism, or insulin induced hypoglycaemia.

END OF REPORT

Lab Director DMC No: 43012



Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No.: | /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 10:03 a.m.

Reporting Time: Mar 08, 2025, 01:57 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

 Test Description
 Value(s)
 Unit(s)
 Reference Range

 HAEMATOLOGY

 Glycated Hb (HbA1c)
 Non-Diabetic
 : <5.7</th>

 HbA1c (Glycated Hemoglobin)
 5.8
 %
 Non-Diabetic
 : <5.7</th>

 Method : EDTA Whole blood, HPLC, NGSP certified
 Pre Diabetes
 : 5.7 - 6.4
 Diabetes
 : ≥ 6.5

Estimated Average Glucose: 119.76 mg/dL

Interpretations

Lab Director DMC No: 43012

- HbA1c has been used as one of the key biomarkers in identifying patients with Diabetes. American Diabetes Association (ADA) and several clinical groups have endorsed utility of HbA1c testing using a cut off value of 6.5%. The average concentration of blood glucose(eBG) is reflected in this test over a period of the past three months.
- · Therapectic goals for monitoring Diabetes.

Goal of therapy < 7% HbA1c.

Action suggested > 8 % HbA1c

- Patients with shortened red cell survival(hemolytic disease), recent significant blood loss have lower HbA1c values .
- High HbA1c is associated with Iron deficiency ,patients with polycythemia or post splenctomy.

Note: The presence of hemoglobin variants can interfere with measurment of HbA1c.

END OF REPORT





Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : I /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m. Receiving Time: Mar 08, 2025, 10:03 a.m. Reporting Time: Mar 08, 2025, 01:19 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

			Nt Code: ACROFEMI HEALTH CARE PVT. LTD. DIWHEEL)
Test Description	Value(s)	Unit(s)	Reference Range
	CLINICAL PA	THOLOGY	
Urine (RE/ME)			
Physical Examination:			
Volume	20		mL
Method : Visual Observation			
Colour	Pale Yellow		Pale Yellow
Method : Visual Observation			
Appearance	Hazy		Clear
Method : Visual Observation			
Reaction (pH)	6.0		4.5 - 8.0
Method : Double Indicator method			
Specific Gravity	1.020		1.010 - 1.030
Method : Ionic Concentration			
Chemical Examination (Dipstick Method) Urine			
Urine Protein	Absent		Absent
Method : Protein Ionisation Heat Test (Acidic Acid)			
Urine Glucose (sugar)	Absent		Absent
Method : Oxidase Reaction/Benedict's			
Blood (Urine)	Absent		Absent
Method : Peroxidase Reaction			
Microscopic Examination Urine			
Red Blood Cells	Absent	/hpf	Absent
Method : Microscopy			
Pus Cells (WBCs)	2 - 4	/hpf	0 - 5
Method : Microscopy			

Red Blood Cells	Absent	/hpf	Absent
Method : Microscopy			
Pus Cells (WBCs)	2 - 4	/hpf	0 - 5
Method : Microscopy			
Epithelial Cells	6 - 8	/hpf	0 - 4
Method : Microscopy			
Cast	Absent		Absent
Method : Microscopy			
Crystals	Absent		Absent
Method : Microscopy			
Amorphous Material	Absent		Absent
Method : Microscopy			
Yeast Cells	Absent		Absent
Method : Microscopy			

Others Bacteria present. Method : Microscopy

Remarks:-





Age / Gender: 49 years / Female

MR No. / IPD No. : /

Patient Type / Bed No. : I /

Referred By: ARCOFEMI HEALTH CARE

PVT.LIMITED (MEDIWHEEL)



Registration Time: Mar 08, 2025, 10:03 a.m.

Receiving Time: Mar 08, 2025, 10:03 a.m.

Reporting Time: Mar 08, 2025, 01:19 p.m.



Panel: Dr Arcofemi Health Care PVT.limited (

MediWheel)

Client Code: ACROFEMI HEALTH CARE PVT. LTD.

(MEDIWHEEL)

Test Description	Value(s)	Unit(s) Reference Range
Epithelial cells		Urolithiasis bladder carcinoma or hydronephrosis ,ureteric stents or bladdercatheters for prolonged periods of time.
Granular casts		Low intratubular pH,high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts		Physical stress, fever, dehydration,acute congestive heart failure, renal diseases.
Calcium Oxalate		Metabolic stone disease, primary or secondary hyperoxaluria, intravenous infusion of large doses of VitaminC, the use of vascodilator naftidrofuryl oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of ethylene glycol or of star fruit(A verrhoa carambola) or its juice
Uric acid		Artharitis
Bacteria		Urinary infection when present in significant numbers and with pus cells.
Trichomonas vaginalis		Vaginitis, cervicitis or salpingitis

END OF REPORT

Dr. Arti Tripathi MD Pathology Lab Director DMC No: 43012